Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL6842282 | 0.99 | MEN1 (0.40) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL4637586 | 0.96 | MEN1 (0.40) | MEN1MAPTKMT2AATML3MBTL1 | |
| SCHEMBL7897410 | 0.95 | MEN1 (0.41) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL7709080 | 0.93 | MEN1 (0.38) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL6111495 | 0.93 | MEN1 (0.44) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL167628 | 0.91 | MEN1 (0.43) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL3257080 | 0.91 | MEN1 (0.45) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL18104019 | 0.91 | MEN1 (0.49) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL6697326 | 0.91 | MEN1 (0.49) | MEN1MAPTKMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL7717187 | 0.91 | MEN1 (0.36) | MEN1MAPTKMT2AATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024101336-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | 国立大学法人京都大学 | 2024-05-16 | — | — | WO | disclosed |
| US-20240101572-A1 | DIHYDROOXADIAZINONE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2024-03-28 | — | — | US | disclosed |
| WO-2023243686-A1 | DIHYDROOXADIAZINONE COMPOUND AND PHARMACEUTICAL USE THEREOF | 日本たばこ産業株式会社 | 2023-12-21 | — | — | WO | disclosed |
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2023-12-05 | — | — | US | disclosed |
| CN-111741948-B | Saturated ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | 日本烟草产业株式会社 | 2023-11-10 | — | — | CN | disclosed |
| EP-3760619-B1 | SATURATED RING-CONDENSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUND, AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2023-10-25 | — | — | EP | disclosed |
| US-11793821-B2 | Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME LLC (US) | 2023-10-24 | — | — | US | disclosed |
| US-11713324-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| CN-110475785-B | Peptide compound, method for producing same, composition for screening, and method for selecting peptide compound | 富士胶片株式会社 | 2023-06-13 | — | — | CN | disclosed |
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | RIKEN (JP) | 2022-08-16 | — | — | US | disclosed |
| EP-0601486-B1 | Cis-epoxide derivatives useful as irreversible HIV protease inhibitors and process and intermediates for their preparation | LUCKY LTD (KR) | 1997-10-29 | — | — | EP | disclosed |
| EP-0787728-A1 | Substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1997-08-06 | — | — | EP | disclosed |
| WO-1997023807-A1 | ELECTRO- OR OPTO-OPTICAL DEVICE STABLE IN THE 600-1600 NANOMETER WAVELENGTH RANGE | AKZO NOBEL N.V. (NL) | 1997-07-03 | — | — | WO | disclosed |
| EP-0779271-A1 | Naphthyl acetamides as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1997-06-18 | — | — | EP | disclosed |
| US-5587388-A | AIDS; VIRICIDES | LUCKY LIMITED (KR) | 1996-12-24 | — | — | US | disclosed |
| CN-1091743-A | Pyrrole derivative, its preparation method and the application in treatment thereof | SYNTHELABO (FR) | 1994-09-07 | — | — | CN | disclosed |
| EP-0601486-A1 | Cis-epoxide derivatives useful as irreversible HIV protease inhibitors and process and intermediates for their preparation | LUCKY LTD. (KR) | 1994-06-15 | — | — | EP | disclosed |
| EP-0199324-B1 | NEW 2,5-DIARYL TETRYHYDROFURANS AND ANALOGS THEREOF AS PAF ANTAGONISTS | MERCK & CO. INC. (US) | 1991-10-02 | — | — | EP | disclosed |
| EP-0322033-A2 | New 2,5-diaryl tetrahydrofurans and analogs thereof as paf antagonists | MERCK & CO. INC. (US) | 1989-06-28 | — | — | EP | disclosed |
| EP-0199324-A2 | New 2,5-diaryl tetryhydrofurans and analogs thereof as paf antagonists | MERCK & CO. INC. (US) | 1986-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | RORC, RORB, RORA | MEN1 3985/4885MAPT 1809/4885KMT2A 1904/4885 |
| US-11793821-B2 | Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors | CHRNA7, CHRNA6, CHRNA5 | MEN1 4885/4885MAPT 379/4885KMT2A 2351/4885 |
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | DPP8, DPP7, AZI2 | MEN1 1930/4885MAPT 3374/4885KMT2A 1226/4885 |
| US-11713324-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | MEN1 566/4885MAPT 4248/4885KMT2A 1468/4885 |
| US-20240101572-A1 | DIHYDROOXADIAZINONE COMPOUND AND PHARMACEUTICAL USE THEREOF | PLD2, PLD1, PLD4 | MEN1 2622/4885MAPT 4171/4885KMT2A 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.